Boston Scientific's first quarter 2026 revenue of $5.2B beats estimates, driven by 13.5% growth in Cardiovascular sales.

Boston Scientific reported first quarter 2026 net sales of $5.203 billion, an increase of 11.6% on a reported basis, and adjusted EPS of $0.80. The results represented a slight beat on revenue expectations and were in line with adjusted EPS estimates, with the company raising its full-year guidance.

Key Highlights

• Revenue of $5.203 billion slightly beat the $5.19 billion estimate, while adjusted EPS of $0.80 met analyst expectations.
• The Cardiovascular segment continued its strong performance, with sales growing 13.5% year-over-year to $3.5 billion, outpacing the MedSurg segment's 7.8% growth.
• Full-year 2026 guidance was raised, with the company now expecting reported net sales growth of 7.0% to 8.5% and adjusted EPS in the range of $3.34 to $3.41.